Healthcare Industry News: Elekta
News Release - April 10, 2006
Elekta to Deliver Sophisticated 3-D Brain Mapping Technology to Leading UK InstitutionSTOCKHOLM, Sweden--(HSMN NewsFeed)--April 10, 2006--Elekta (STO:EKTA) has won a tender to deliver Elekta Neuromag®, the world-leading equipment for non-invasive registration of nerve cell activity using magnetoencephalography (MEG) technology to the renowned centre for research in cognitive neuroscience, the MRC Cognition and Brain Sciences Unit (MRC CBU) in Cambridge, UK.
MRC CBU will now be able to non-invasively register nerve cell activity in the brain in real time, using the ability of the MEG technology to measure the intensity of very weak magnetic fields generated by electrical activity in the brain. This diagnostic tool increases the ability to understand and to improve treatment of functional disorders.
MEG is presently regarded as the most efficient method for tracking brain activity in real-time for many reasons. Compared to EEG, MEG has unique sensitivity capabilities. MEG also offers functional mapping information and measurement of brain activity in real time, unlike Computer Tomography (CT) and Magnetic Resonance Imaging (MRI and fMRI) which only provide structural, anatomical and metabolic information.
"The scope of the research collaboration agreement offered by Elekta Neuromag, and the associated benefits, were an important component of the added value brought to the MRC CBU by the Elekta tender." says Professor William Marslen-Wilson, Director of the MRC CBU.
He continues: "The MRC CBU has just installed one of the most advanced machines in the UK for haemodynamic measurement, in the form of its newly commissioned MRI facility. The addition of a magnetoencephalographic (MEG) scanner from Elekta, offering excellent performance in the temporal domain, will put the CBU in a highly competitive situation to meet the challenge of relating brain activity to normal and disordered cognitive function. We are very much looking forward to installing the Elekta Neuromag system in the autumn of this year."
"Non-invasive, real-time brain mapping and monitoring is considered as one of the most exciting developments in neuroscience today and around the world researchers and clinicians are developing functional neuroimaging MEG protocols. The list of new applications is steadily growing and this contract between Elekta and CBU is an important step in that progress", says David Miles, Elekta's Business Unit Managing Director for the UK& Ireland.
Cognition and Brain Sciences Unit
Cognition and Brain Sciences Unit (CBU) constitutes one of the largest concentrations of cognitive scientists and neuroscientists on a single site anywhere in the world, with nearly 100 active scientists, students and research staff. A priority in the CBU research strategy over the last 5 years has been to develop a strong research program in neuro imaging, working closely with the Cambridge partners and now at a dedicated imaging facility on its own site. More than half of the scientific staff and students are actively involved in neuro imaging projects. From emotions and memories to language and learning, functional neuroimaging is being applied in many different areas of cognitive neuroscience. In many cases, this research relies upon support from healthy volunteers although neuroimaging studies are also being conducted in various clinical populations, including depression, anxiety, Parkinson's disease and Alzheimer's disease.
Elekta Neuromag 306 MEG channels sensor array has higher density than any other system on the market and thus covers the brain better with a better representation of brain activity than any other MEG system. With the industry's lowest noise to signal ratio, meaning that more useful information is acquired, and thus also the highest yield of information per sample.
The unique design of the sensors combined with advanced software makes it possible to gain data with unsurpassed detail even from the deepest realms of the brain. The system also has the highest available immunity to magnetic interference, either patient-related or external. Elekta Neuromag has also the lowest operational costs, with the longest liquid helium refill interval. Elekta Neuromag is technically one of the most sophisticated MEG/EEG devices available on the market today.
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.
Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approx. 1850 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.Elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.